摘要
目的 回顾性分析经动脉灌注健择 (盐酸吉西他滨 )治疗中晚期胰腺癌临床疗效。方法 13例中晚期胰腺癌患者接受动脉灌注健择治疗。治疗后观察肿瘤改善情况及临床受益反应 (CBR)。结果 PR 1例 ( 7 7% ) ,NC 3例 ( 2 3 % ) ,SD 3例 ( 2 3 % ) ,6例无法评价。Kaplan Meier法计算 6个月累积生存率为 46 88% ,频数分布法计算中位生存期为 5 5个月 ,中位进展期为 2 6 9个月。临床受益率为 30 76 % (与文献相比P <0 0 0 1)。结论 无论对于初治或化疗无效的病人 ,动脉灌注健择均显示出良好的临床受益反应 ;
Purpose The effectiveness of transarterial infusion chemotherapy of gemcitabine for management of advanced pancreatic carcinoma was retrospectively analyzed. Methods Gemcitabine was administered to 13 patients with advanced pancreatic carcinoma via an interarterial catheter.Karnofsky performance score was (KPS)>50. Results Of 1 patient (7 7%) obtained partial response (PR), and 3 patients (23%) achieved no change of their disease.Probability for 6 month cumulative survival rate was 46 88%,median survival period was 5 5 months.No serious side effects were observed.Clinical benefit response (CBR) was 30 76%.The median time to progression was 2 69 months. Conclusion Transarterial infusion of gemcitabine appears well tolerated and promising CBR in patients with advanced pancreatic carcinoma. [
出处
《中国医学影像技术》
CSCD
北大核心
2000年第11期928-930,共3页
Chinese Journal of Medical Imaging Technology
基金
国家"九五"攻关资助项目 !(96 90 7 0 3 0 5 )
关键词
胰腺癌
动脉灌注化疗
临床受益反应
Pancreatic carcinoma
Gemcitabine
Transarterial chemotherapy
Clinical benefit response
